Hangzhou Tigermed Consulting Co., Ltd (HNGZY)
OTCMKTS · Delayed Price · Currency is USD
4.000
-0.140 (-3.38%)
At close: Dec 24, 2024
HNGZY Revenue
Hangzhou Tigermed Consulting had revenue of 1.78B CNY in the quarter ending September 30, 2025, with 3.86% growth. This brings the company's revenue in the last twelve months to 6.56B, down -3.53% year-over-year. In the year 2024, Hangzhou Tigermed Consulting had annual revenue of 6.60B, down -10.58%.
Revenue (ttm)
6.56B CNY
Revenue Growth
-3.53%
P/S Ratio
8.43
Revenue / Employee
640.07K CNY
Employees
10,251
Market Cap
7.77B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.60B | -780.92M | -10.58% |
| Dec 31, 2023 | 7.38B | 298.57M | 4.21% |
| Jan 1, 2023 | 7.09B | 1.87B | 35.91% |
| Jan 1, 2022 | 5.21B | 2.02B | 63.32% |
| Dec 31, 2020 | 3.19B | 388.97M | 13.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Global Cord Blood | 196.10M |
| Centogene | 53.65M |
| Bioqual | 46.54M |
| Interpace Biosciences | 41.92M |
| Psychemedics | 19.69M |
| China New Energy Group Company | 12.51M |
| Aspira Women's Health | 9.34M |
| Longduoduo Company | 2.72M |
Hangzhou Tigermed Consulting News
- 26 days ago - Hangzhou Tigermed Consulting Co., Ltd (HNGZY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 1 year ago - Hangzhou Tigermed Consulting reports Q2 results - Seeking Alpha